FDA partner Julie Tibbets highlights the growing need for companies, showcasing innovative and marketed drug products at large medical meetings, to beware of the U.S. Food and Drug Administration’s Office of Prescription Drug Promotion increased efforts targeting and enforcing exhibit booth content in recent years.
Read the full article.
Related Content
- InsightApril 1, 2024
A Look Ahead in Life Sciences: What We Are Tracking in Q2 2024 and Beyond
- InsightOctober 13, 2023
FDA’s Proposed Rule for Oversight of Laboratory Developed Tests: Part II: FDA’s Proposed Phaseout Policy – Key Considerations & Open Questions
- InsightOctober 6, 2023
FDA’s Proposed Rule for Oversight of Laboratory Developed Tests: Part I: Underpinnings of FDA’s Proposed Rule
- AlertSeptember 15, 2023
Modernizing the FDA’s 510(k) Program for Medical Devices: Selection of Predicate Devices and Use of Clinical Data in 510(k) Submissions
- InsightJune 29, 2023
A Look Ahead in Life Sciences: What We Are Tracking in Q3 2023 and Beyond
- InsightMay 24, 2023
Top IP, FDA, and Compliance Issues for Medtech Companies Transitioning to Data-Enabled Product Solutions
- AlertApril 5, 2023
CMS Issues Guidance and Solicits Comment on the 2026 Inflation Reduction Act Part D Negotiation Process
- AlertMarch 15, 2023
The Long (Un)Winding Road: FDA Maps Out How the End of the Public Health Emergency Will Impact its COVID-19 Policies
- Press ReleaseApril 18, 2024
Lumicell’s Novel Optical Imaging Agent Platform LUMISIGHT™ & Direct Visualization System for Detection of Residual Breast Cancer Receives FDA Approval
- Press ReleaseApril 17, 2024
Abingworth to Provide Teva with up to $150 Million in Financing to Advance Treatment of Asthma
- Awards and RankingsMarch 20, 2024
The American Lawyer Names Rachael Bushey and Jennifer Porter 2024 Dealmakers of the Year
- In the PressMarch 6, 2024
Eidos Therapeutics Signs Exclusive License Agreement with Bayer
- Press ReleaseFebruary 9, 2024
BridgeBio Pharma and QED Therapeutics License Skeletal Dysplasias Treatments to Kyowa Kirin for an Upfront Payment of $100 Million Plus Milestones
- Press ReleaseFebruary 1, 2024
AVROBIO To Combine With Tectonic Therapeutic In All-Stock Transaction
- Press ReleaseJanuary 16, 2024
Myrobalan Therapeutics Completes Series A Financing of $24 Million to Develop Potentially First-in-Class CNS Therapeutics with Restorative Potential
- Press ReleaseJanuary 10, 2024
Goodwin Releases Update to its Comprehensive Guide to Biosimilars Litigation and Regulation in the U.S.